Effects of clodronate on cortical and trabecular bone in ovariectomized rats on a low calcium diet
- PMID: 9236265
- DOI: 10.1007/s002239900315
Effects of clodronate on cortical and trabecular bone in ovariectomized rats on a low calcium diet
Abstract
The aim of this study was to evaluate the contribution of a low calcium diet to the cortical and trabecular osteoporosis seen in ovariectomized rats after 7 weeks on a low calcium diet and to investigate the effects of the bisphosphonate clodronate on this development of osteoporosis. Thirty-six mature, female Wistar rats were randomized into four groups: Ovx-B (bisphosphonate) and Ovx-C (control) were ovariectomized, and Sham-Ca (low calcium) and Sham+Ca (normal calcium) were sham operated. The first three groups were fed a low calcium diet (0.01%) and Sham+Ca normal rat chow (Ca 1.1%). The Ovx-B received 10 mg/kg s.c. clodronate daily for nine weeks, and Ovx-C, Sham-Ca, and Sham+Ca received the same volumes of saline. Bone mineral turnover measured as 85Sr-uptake was increased in all low calcium groups compared to Sham+Ca. The Sham+Ca femora had higher dry weight and ash weight than the other groups, and Ovx-C had higher dry weight compared with Ovx-B and Sham-Ca. Calcium content was lower in both Ovx groups compared to both Sham groups. Magnesium was lower in all groups compared to Sham+Ca and higher in Ovx-B compared with Ovx-C. In the femoral shaft, Sham+Ca had significantly higher ultimate bending moment, energy absorption, and deflection compared to the other three groups. Ultimate bending moment was higher in Sham-Ca than in Ovx-C. Stiffness was increased in both Sham+Ca and Ovx-B compared to Ovx-C. The maximum stress in the femoral midshaft was higher in Sham+Ca than in the other groups, and higher in Ovx-B than in Ovx-C. Histomorphometry showed increased medullary area in all low calcium groups compared to Sham+Ca and larger cortical area in Sham+Ca and Ovx-B compared to Ovx-C. Compared to Sham+Ca the trabecular bone volume was decreased to 30% in Sham-Ca and to 9% in Ovx-C, but was unchanged in Ovx-B. The low calcium diet generally increased bone mineral turnover and reduced the tibial bone volume. Femoral changes led to a reduction of cortical fracture strength and maximal stress. Ovariectomy in addition to a low calcium diet reduced femoral strength even more. Daily injections of clodronate to ovariectomized rats on a low calcium diet increased femoral shaft stiffness and maximum stress, and clodronate preserved both trabecular and cortical tibial bone volume completely.
Similar articles
-
Effect of clodronate treatment on established bone loss in ovariectomized rats.Bone. 1998 Oct;23(4):333-42. doi: 10.1016/s8756-3282(98)00110-0. Bone. 1998. PMID: 9763145
-
The effect of orally administered clodronate on bone mineral density and bone geometry in ovariectomized rats.J Pharmacol Exp Ther. 1998 Jan;284(1):312-6. J Pharmacol Exp Ther. 1998. PMID: 9435193
-
The effects of clodronate on increased bone turnover and bone loss due to ovariectomy in rats.Bone. 1995 Dec;17(6):533-42. doi: 10.1016/8756-3282(95)00388-6. Bone. 1995. PMID: 8835307
-
Vitamin D deficiency and ovariectomy reduced the strength of the femoral neck in rats.Calcif Tissue Int. 2001 Aug;69(2):102-8. doi: 10.1007/s00223-001-0009-2. Calcif Tissue Int. 2001. PMID: 11683422
-
Ovariectomized rat model of osteoporosis: a practical guide.EXCLI J. 2020 Jan 10;19:89-107. doi: 10.17179/excli2019-1990. eCollection 2020. EXCLI J. 2020. PMID: 32038119 Free PMC article. Review.
Cited by
-
Effect of modulating dietary vitamin D on the general bone health of rats during posterolateral spinal fusion.J Orthop Res. 2018 May;36(5):1435-1443. doi: 10.1002/jor.23832. Epub 2018 Jan 16. J Orthop Res. 2018. PMID: 29266465 Free PMC article.
-
Risedronate improves bone architecture and strength faster than alendronate in ovariectomized rats on a low-calcium diet.J Bone Miner Metab. 2014 Nov;32(6):653-9. doi: 10.1007/s00774-013-0543-9. Epub 2013 Dec 20. J Bone Miner Metab. 2014. PMID: 24357144
-
A tolerability and pharmacokinetic study of a new injectable formulation of disodium clodronate in healthy female volunteers.Eur J Drug Metab Pharmacokinet. 2004 Apr-Jun;29(2):145-52. doi: 10.1007/BF03190589. Eur J Drug Metab Pharmacokinet. 2004. PMID: 15230343 Clinical Trial.
-
Clodronate: a review of its use in breast cancer.Drugs Aging. 1999 Aug;15(2):143-67. doi: 10.2165/00002512-199915020-00007. Drugs Aging. 1999. PMID: 10495073 Review.
-
Improved efficacy of intramuscular weekly administration of clodronate 200 mg (100 mg twice weekly) compared with 100 mg (once weekly) for increasing bone mineral density in postmenopausal osteoporosis.Clin Drug Investig. 2013 Mar;33(3):193-8. doi: 10.1007/s40261-013-0062-4. Clin Drug Investig. 2013. PMID: 23456672 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous